Drugs / allogeneic lymphocytes
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00003552 | Jan 1999 → Oct 2002 | melanoma | National Heart, Lung, and Blood Institute (NHLBI) | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00020176 | Jun 2000 → Aug 2007 | breast cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00110058 Background | Feb 2005 → Jul 2006 | leukemia | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | allogeneic lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00020176 ↗ |
| Known as | allogeneic T lymphocytes | “Allogeneic T lymphocytes can induce regression of metastatic breast cancer through an immune-mediated graft-versus-tumor (GVT) effect” PMID 15314059 ↗ Aug 2004 |
| Modality | Cell therapy | “allogeneic T-cell infusion as adoptive immunotherapy” NCT00003552 ↗ |
| Route | Intravenous | “receive donor lymphocytes IV on days 42, 70, and 98” NCT00020176 ↗ |